Theranostic agents are promising due to their ability to diagnose, treat and monitor different types of cancer using a variety of imaging modalities. The advantage specifically of nanoparticles is that they can accumulate easily at the tumor site due to the large gaps in blood vessels near tumors. Such high concentration of theranostic agents at the target site can lead to enhancement in both imaging and therapy. This article provides an overview of nanoparticles that have been used for cancer theranostics, and the different imaging, treatment options and signaling pathways that are important when using nanoparticles for cancer theranostics. In particular, nanoparticles made of metal elements are emphasized due to their wide applications in cancer theranostics. One important aspect discussed is the ability to combine different types of metals in one nanoplatform for use as multimodal imaging and therapeutic agents for cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467409 | PMC |
http://dx.doi.org/10.1177/15330338231191493 | DOI Listing |
ACS Biomater Sci Eng
March 2025
Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Science and Technology, Shandong Second Medical University, Weifang 261000 P. R. China.
Improvements in tumor therapy require a combination of strategies where targeted treatment is critical. We developed a new versatile nanoplatform, MA@E, that generates high levels of reactive oxygen species (ROS) with effective photothermal conversions in the removal of tumors. Enhanced stability liposomes were employed as carriers to facilitate the uniform distribution and stable storage of encapsulated gold nanorods (AuNRs) and Mn-MIL-100 metal-organic frameworks, with efficient delivery of MA@E to the cytoplasm.
View Article and Find Full Text PDFInt J Nanomedicine
March 2025
Department of Ultrasound, the Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Introduction: Triple-negative breast cancer (TNBC) is known for its high malignancy, limited clinical treatment options, and poor chemotherapy outcomes. Although some advancements have been made using nanotechnology-based chemotherapy for TNBC treatment, the controlled and on-demand release of chemotherapeutic drugs at the tumor site remains a challenge.
Methods: We manufactured DOX/BaTiO@cRGD-Lip (DBRL) nanoparticles as an ultrasound (US)-controlled release platform targeting the delivery of Doxorubicin (DOX) for TNBC treatment.
Research (Wash D C)
March 2025
Department of General Surgery, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
Exosomes (Exos) are emerging as noninvasive biomarkers for diagnosis and progression monitoring of gastric cancer (GC). However, the heterogeneity discrimination and ultrasensitive quantification of Exos presents a considerable analytical challenge, thereby impeding severely their clinical application. Herein, we propose an integrated terahertz metasensing platform for the discrimination of Exos in distinct subtypes of GC in a single step-through the simultaneous evaluation of the category and richness level of Exos membrane proteins.
View Article and Find Full Text PDFIran J Pharm Res
November 2024
Department of Tissue Engineering and Applied Cell Sciences, Faculty of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Background: Invasive cervical cancer is recognized as the second most common malignancy in women after breast cancer.
Objectives: This study investigates, for the first time, the effect of gold nanoparticle-doped graphene oxide (GO) nanosheets on the human epithelial carcinoma (HeLa) cell line in the presence of heliox cold plasma.
Methods: Graphene oxide nanosheets were synthesized using the Hummer method and then doped with gold nanoparticles.
Front Oncol
February 2025
Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China.
Background: Treatment of hypopharyngeal carcinoma involves surgery, radiotherapy, and chemotherapy. The combination of docetaxel, cisplatin, and 5-fluorouracil as a standard induction chemotherapy regimen allows enhanced laryngeal preservation after surgery. In this study, our objective was to retrospectively analyze the short-term efficacy and adverse events of nab-paclitaxel plus cisplatin or nedaplatin plus tegafur/gimeracil/oteracil as an induction chemotherapy regimen for hypopharyngeal cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!